Tony R. Hazbun
Biochemistry, Genetics and Molecular Biology · Purdue University West Lafayette
Publications
79
Citations
2,558
Est. group size
~2
Recurring co-author estimate
Active years
29
Publishing since 1997
Tony R. Hazbun's research focuses on yeast and fungal molecular biology, including protein modifications (like N-terminal methylation), cell division in dormant (stationary-phase) yeast cells, and the discovery of drugs to fight fungal infections such as Cryptococcus and drug-resistant Candida. Related work also touches on protein phosphorylation pathways linked to cancer drug resistance and genetic disorders like Lowe Syndrome. This research combines basic biochemistry with applied drug-repurposing and disease-relevant genetics.
Publication output has fluctuated over the past decade, with a notable spike in 2023 (largely due to supplementary materials from a single study) followed by a decline in 2024-2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- In vitro and in vivo efficacy of the antimycobacterial molecule SQ109 against the human pathogenic fungus, Cryptococcus neoformans
PLoS neglected tropical diseases · 2025
- Coordinated Division of Selective Stationary-Phase Yeast Cells Expands the Population Survivorship in Quiescence
bioRxiv (Cold Spring Harbor Laboratory) · 2024
- Unlocking the mysteries of alpha-N-terminal methylation and its diverse regulatory functions
Journal of Biological Chemistry · 2023
- Data from Plk1 Phosphorylation of Orc2 and Hbo1 Contributes to Gemcitabine Resistance in Pancreatic Cancer
2023
- Supplementary Figure 2 from Plk1 Phosphorylation of Orc2 and Hbo1 Contributes to Gemcitabine Resistance in Pancreatic Cancer
2023
- Supplementary Table 1 from Plk1 Phosphorylation of Orc2 and Hbo1 Contributes to Gemcitabine Resistance in Pancreatic Cancer
2023
- Supplementary Methods and Figure Legends from Plk1 Phosphorylation of Orc2 and Hbo1 Contributes to Gemcitabine Resistance in Pancreatic Cancer
2023
- Supplementary Figure 3 from Plk1 Phosphorylation of Orc2 and Hbo1 Contributes to Gemcitabine Resistance in Pancreatic Cancer
2023
- Supplementary Figure 4 from Plk1 Phosphorylation of Orc2 and Hbo1 Contributes to Gemcitabine Resistance in Pancreatic Cancer
2023
- Supplementary Figure 4 from Plk1 Phosphorylation of Orc2 and Hbo1 Contributes to Gemcitabine Resistance in Pancreatic Cancer
2023
- Supplementary Table 1 from Plk1 Phosphorylation of Orc2 and Hbo1 Contributes to Gemcitabine Resistance in Pancreatic Cancer
2023
- Supplementary Methods and Figure Legends from Plk1 Phosphorylation of Orc2 and Hbo1 Contributes to Gemcitabine Resistance in Pancreatic Cancer
2023
- Supplementary Figure 2 from Plk1 Phosphorylation of Orc2 and Hbo1 Contributes to Gemcitabine Resistance in Pancreatic Cancer
2023
- Supplementary Figure 1 from Plk1 Phosphorylation of Orc2 and Hbo1 Contributes to Gemcitabine Resistance in Pancreatic Cancer
2023
- Supplementary Figure 1 from Plk1 Phosphorylation of Orc2 and Hbo1 Contributes to Gemcitabine Resistance in Pancreatic Cancer
2023
- Scientific Reports×5
- bioRxiv (Cold Spring Harbor Laboratory)×4
- Antimicrobial Agents and Chemotherapy×3
- Biochimica et Biophysica Acta (BBA) - General Subjects×2
- Emerging Microbes & Infections×2
- Soni Lacefield
Biochemistry, Genetics and Molecular Biology · Indiana University
- Kevin P. Weller
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Xiaoqi Liu
Biochemistry, Genetics and Molecular Biology · Purdue University West Lafayette
- Gisela Cairo
Biochemistry, Genetics and Molecular Biology · Indiana University
- Keith Viccaro
Biochemistry, Genetics and Molecular Biology · Purdue University West Lafayette
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 20, 2026.
Claim or correct this profile